Adaptive Biotechnologies (ADPT) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Adaptive Biotechnologies (ADPT) right now is clonoSEQ MRD volume and reimbursement: The core driver is clonoSEQ test volume, which grew about 41 percent year over year in the first quarter of 2026 to more than 32,000 tests. Revenue (TTM) is ~$250M. If that keeps playing out, the setup is favourable; the risk to it is aDPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. No one can predict where ADPT trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Adaptive Biotechnologies (ADPT) higher?
1. clonoSEQ MRD volume and reimbursement
The core driver is clonoSEQ test volume, which grew about 41 percent year over year in the first quarter of 2026 to more than 32,000 tests. Expanding clinical guidelines, broader payer coverage, and adoption in additional blood-cancer indications support continued volume growth. Because MRD is roughly 95 percent of revenue, this is the metric that moves the story.
2. Pharma and biopharma partnerships
Beyond clinical testing, drugmakers use the MRD platform as a trial endpoint, and the company recognized milestone revenue tied to regulatory progress, including its first U.S. primary-endpoint milestone in early 2026. These partnerships add higher-margin, lumpier revenue on top of the recurring clinical test base. They also validate MRD as an accepted measure in oncology drug development.
3. Path to profitability
Net loss narrowed and adjusted EBITDA loss shrank toward breakeven in early 2026 as the MRD business scaled, a notable shift for a company that historically burned cash. Management has framed MRD as having reached profitability on a standalone basis. Continued operating leverage is central to the bull framing.
4. Planned MRD / Immune Medicine separation
In June 2026 the company announced plans to separate its scaled, profitable MRD business from the earlier-stage Immune Medicine unit, with a preferred path expected by year-end 2026. A split could let the market value a clean diagnostics grower on its own while isolating the drug-discovery risk. The structure and timing remain unsettled.
What could weigh on ADPT?
ADPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. The MRD diagnostics market is competitive, with Natera, Guardant Health, Exact Sciences, and NeoGenomics all pushing MRD and liquid-biopsy offerings, and reimbursement decisions can swing revenue. Pharma milestone revenue is lumpy and hard to forecast quarter to quarter. The announced business separation adds execution and structural uncertainty, and the Immune Medicine drug programs, including the Genentech-linked work, are early stage with binary outcomes. The stock has also been volatile, trading across a wide 52-week range.
Where ADPT trades today
A forecast starts from where the stock actually is. These are ADPT's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for ADPT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a ADPT forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ADPT guide and whether ADPT is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ADPT outlook
The bottom line: what is driving Adaptive Biotechnologies (ADPT) is clonoSEQ MRD volume and reimbursement, with revenue (ttm) at ~$250M. If that keeps playing out the setup is favourable; the risk is aDPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. No one can predict the price, so treat any ADPT forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ADPT with Walnut
Use Adaptive Biotechnologies as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Adaptive Biotechnologies (ADPT)?
+
No one can reliably predict where ADPT will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Adaptive Biotechnologies higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ADPT higher?
+
The main growth drivers are clonoSEQ MRD volume and reimbursement; Pharma and biopharma partnerships; Path to profitability. Whether they play out is the real question, not a guaranteed path.
What are the risks to ADPT?
+
ADPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. The MRD diagnostics market is competitive, with Natera, Guardant Health, Exact Sciences, and NeoGenomics all pushing MRD and liquid-biopsy offerings, and reimbursement decisions can swing revenue. Pharma milestone revenue is lumpy and hard to forecast quarter to quarter. The announced business separation adds execution and structural uncertainty, and the Immune Medicine drug programs, including the Genentech-linked work, are early stage with binary outcomes. The stock has also been volatile, trading across a wide 52-week range.
Will ADPT stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Adaptive Biotechnologies's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ADPT a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ADPT "is it a buy?" page for a framework. Walnut is not an investment adviser.
How fast is ADPT growing?
+
First-quarter 2026 revenue rose about 35 percent year over year to roughly $70.9 million, with MRD revenue up about 53 percent and clonoSEQ volume up about 41 percent. The company raised full-year MRD guidance toward roughly $260 million to $270 million.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.